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ABSTRACT
Campylobacter jejuni is a leading cause of bacterial-derived gastroenteritis
worldwide. In the developed world, campylobacteriosis is most commonly
acquired following the consumption of cross contaminated foods or undercooked
poultry meat, since the bacterium asymptomatically colonizes chickens. In the
developing world, infection most commonly occurs through drinking
contaminated water. Following ingestion, Campylobacter adheres to the intestinal
epithelium and mucus layer, causing toxin-mediated inflammation and inhibition
of fluid reabsorption. Currently, the bacterial mechanisms behind colonization
and disease are relatively unknown. Thus, it is important to identify factors that
influence the development of these sequelae during and after initial C. jejuni
infection.
Ferrets (Mustela putorius furo) have been previously used as an animal
model of human campylobacteriosis, but intensive investigation into this model
has yet to be performed. Thus, in this study, we non-invasively examined for
disease in ferrets and determined whether there were any effects on
development following infection with C. jejuni. Ferrets were effectively colonized
by C. jejuni with peak fecal loads observed at day 3 post-infection, and with full
resolution by day 12 post-infection. Infected male ferrets had reduced weight
when compared to uninfected males early in infection, but this was resolved by
the conclusion of the experiment. All infected ferrets exhibited reduced activity
and minor changes in fecal consistency. Cytokine levels in serum increased in
iv

response to infection, with significance observed for IL-10 and TNFD (tumor
necrosis factor alpha). Occult blood was observed in both uninfected and
infected cohorts. Additionally, in response to infection, the neutrophil protein
calgranulin C (S100A12) was found to be increased in the feces of both ferrets
and humans infected with C. jejuni, while calprotectin (another neutrophil protein)
was not. The addition of either purified S100A12 or of calprotectin to in vitro
cultures of C. jejuni was found to inhibit growth in a zinc-dependent manner.
These results suggest that upon infection with C. jejuni, neutrophils that are
trafficked to the intestine release S100A12 and possibly calprotectin as a
mechanism for inhibiting C. jejuni growth in the intestine.
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CHAPTER ONE
INTRODUCTION AND GENERAL INFORMATION

Campylobacter
Campylobacter is a Gram-negative, rod-shaped member of the group
Epsilonproteobacteria, and is closely related to Helicobacter. It is a motile
organism that typically has either a single polar flagellum or bipolar flagella and
moves in a corkscrew fashion (Fonseca, Fernández, & Rossi, 2016).
Campylobacter is a microaerophile that grows preferentially between 37qC and
42qC (Penner, 1988). Although this bacterium cannot grow in vitro at
temperatures below 37qC, it is able to survive and perform basic metabolic
functions at temperatures as low as 4qC (Hazeleger et al., 1998). This explains
how some Campylobacter species can survive on stored poultry meat for
extended periods of time and resume proper function once ingested. Several
Campylobacter species reside asymptomatically in the gastrointestinal tract of
chickens and other domestic livestock. Chickens become colonized early in life
(approximately 2-3 weeks after hatching) and are typically colonized for life
(Sahin et al., 2013).
Some thermotolerant species of Campylobacter, such as C. jejuni, C. coli,
and C. lari, can infect humans and cause bacterial gastroenteritis (Penner, 1988).
C. jejuni and C. coli are the most common causes of Campylobacter infection.
Campylobacteriosis typically produces symptoms such as acute mild to severe
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watery or bloody diarrhea, fever, and abdominal pain. Symptoms last
approximately one week and the onset of symptoms occurs 24 to 72 hours
following ingestion (Man, 2011). In developing countries, infection most
commonly occurs through drinking contaminated water. Children five years of
age and younger are particularly susceptible to infection, which may lead to
persistent colonization in the gastrointestinal tracts of these children. Although
campylobacteriosis symptoms do not tend to last much longer, this persistence
can cause further complications such as stunting (Amour et al., 2016). In the
developed world, Campylobacter infection is most commonly acquired through
the consumption of contaminated meat, and young adults (15-24 years old) as
well as children are susceptible to infection (Friedman et al., 2000).
Campylobacter is typically self-limiting in immunocompetent patients, but
can lead to more serious diseases and higher instances of death in those
persistently colonized, people with compromised immune systems, young
children, and the elderly (Amour et al., 2016; Coker et al., 2002). Complications
such as Guillian-Barré syndrome, septicemia, reactive arthritis, and Miller Fisher
syndrome can occur following campylobacteriosis (Goldstein et al., 2016).
Campylobacter has also been linked to certain irritable bowel diseases such as
ulcerative colitis and Crohn’s disease (Kaakoush et al., 2014). Studies have
shown that up to 80% of all fresh broiler chicken meat is contaminated with
Campylobacter (EFSA, 2014). The estimated cost of campylobacteriosis and
resulting complications is approximately $1.7 billion annually in the United States
2

alone (Maue et al., 2014). The high cost, serious complications, and ease of
infection of Campylobacter makes it a priority to study.
C. jejuni
Campylobacter jejuni accounts for approximately 90% of all
campylobacteriosis cases (Gillespie et al., 2002). This bacterial species alone is
the most common cause of food-borne bacterial-derived gastroenteritis in the
world and it is estimated that as much as 80% of all poultry carcasses in the
European Union are contaminated with C. jejuni (European Food Safety
Authority, 2010). Previously, it was thought that C. jejuni colonizes chickens
without causing any physiological signs of illness (Hermans et al., 2012).
However, a more recent study shows that C. jejuni colonization in broilers does
provoke an inflammatory immune response, and that the level of inflammation
stays elevated in certain breeds. This was seen by the elevated levels of the
proinflammatory cytokines CXCLi1, CXCLi2, and IL-1E. Additionally, the authors
of this study found increased incidences of diarrhea in chickens colonized by C.
jejuni, which may be linked to skin disorders found in these birds, such as
pododermatitis, as well as damage to the intestinal mucosa (Humphrey et al.,
2014).
Under harsh environmental conditions, such as in aquatic environments or
on abiotic surfaces, C. jejuni is able to form biofilms (Maal-Bared et al., 2012).
Aerobic and low nutrient environments promote the formation of these biofilms
(Reeser et al., 2007; Reuter et al., 2010). Although the mechanism of C. jejuni
3

biofilm formation is unknown, studies have shown that this ability requires
quorum sensing, functioning flagella and certain surface proteins (Asakura et al.,
2007; Reeser et al., 2007). Studies have also shown that when in a biofilm, C.
jejuni changes the regulation of certain genes. More specifically, it has been
shown that iron uptake is upregulated, as well as proteins that are used for
oxidative defense and membrane transport (Sampathkumar et al., 2006).
Campylobacter biofilm formation may hint at a method of preventing C. jejuni
infection in humans, as different strains of C. jejuni have been seen to have
varying levels of ability to form biofilms due to mutations in either a putative
flagellar protein or a phosphate acetyltransferase (Joshua et al., 2006).
C. coli
While Campylobacter jejuni is responsible for approximately 90% of all
campylobacteriosis cases worldwide, C. coli accounts for approximately 10% of
all cases (Gillespie et al., 2002). C. jejuni is typically the most abundant species
of Campylobacter present in chickens and cattle (Thakur et al., 2006). However,
C. coli has been shown to be more prevalent in broiler meat than C. jejuni in
some countries (European Food Safety Authority, 2010; Torralbo et al., 2015).
Additionally, C. coli is known to be more prevalent in pigs than C. jejuni (Thakur
et al., 2006). Increasingly, incidences of C. coli are becoming more prevalent.
One study reports that C. coli may be responsible for as high as 25% of all
Campylobacter-related enterocolitis (Man, 2011). C. jejuni and C. coli share
many of the same pathological symptoms. A recent case study has even shown
4

evidence for C. coli’s ability to cause the rare campylobacteriosis complication
myopericarditis (Moffatt, Moloi, & Kennedy, 2017). Fortunately, serious
campylobacteriosis complications such as myopericarditis rarely cause
prolonged damage or death (Imazio et al., 2014). It is speculated that such
complications are caused by excessive antibiotic treatment of
campylobacteriosis, as antibiotics are commonly used as a treatment for
Campylobacter infection, since there is no standard for how long antibiotics
should be given or at what dosage (Hessulf et al., 2016).
Other Strains
Although C. jejuni and C. coli are the main causes of campylobacteriosis,
other Campylobacter strains have been shown to cause disease (Meunier et al.,
2016b). For instance, C. concisus is a strain of Campylobacter often found in
human oral cavities of both diseased and healthy individuals (Zhang et al., 2010;
Peterson et al., 2007). Although harmless to the oral cavitiy, C. concisus has
been linked to triggering inflammatory bowel disease (Zhang et al., 2014).
Similarly, C. rectus can be found in the human oral cavity. However, this
Campylobacter species is known to cause periodontitis as well as gastrointestinal
symptoms (Mahlen & Clarridge, 2009). C. rectus may also lead to complications
such as Crohn’s disease and ulcerative colitis (Mukhopadhya et al., 2011; Man et
al., 2010), and has been seen to cause severe acute otitis media under certain
circumstances (Kakuta et al., 2016). C. fetus, a strain often found in cattle and
sheep, produces the typical gastrointestinal symptoms associated with
5

campylobacteriosis in humans as well as systemic infections in rare cases
(Wagenaar et al., 2014). Certain subspecies of C. fetus may also cause
spontaneous abortion both in humans and in cattle (Fujihara et al., 2006; Mshelia
et al., 2010). C. curvus is a relatively new Campylobacter species that is rarely
found in humans, but when present may cause severe diarrhea (Abbott et al.,
2005). Additionally, in a more recent study, C. curvus was present in a vaginal
infection and may have contributed to premature birth (Mendz et al., 2014).
Campylobacter lari is another species that is rarely isolated from humans, but is
known to cause enteritis, bacteremia, and urinary tract infections (Bézian et al.,
1990). C. lari has also been seen to infect prosthetics, and such an infection
resulted in the death of an immunocompetent patient (Werno et al., 2002).

Campylobacter Mechanism of Infection
Little is known about how Campylobacter is able to successfully infect
humans and colonize chickens. C. jejuni, the most prevalent Campylobacter
species, typically resides in the cecal mucosal crypts of colonized birds (Coward
et al., 2008). Campylobacter counts as high as 108 CFU (colony forming
units)/gram of cecal contents has been isolated from chicken cecal mucosa
(Meade et al., 2009). Although it is generally accepted that this colonization has
no effect on birds, evidence has recently suggested that Campylobacter does
indeed promote an immune response in these animals, and that this response
can be damaging to the intestines (Humphrey et al., 2014). Many efforts to
6

control or reduce Campylobacter loads in broiler farms have proven to be
ineffective, perhaps in part due to the lack of knowledge of how this bacterium is
spread to chickens. Several studies have demonstrated that Campylobacter is
highly unlikely to be spread from breeder hens to eggs, either due to the difficulty
of this pathogen infecting the chick or the lack of similarity in the genotypes of C.
jejuni isolated from breeder hens compared to those later isolated from broilers
(Jacobs-Reitsma, 1995; Sahin, Kobalka, & Zhang, 2003; O’Mahoney et al., 2011;
Patriarchi et al., 2011). Instead, it has been shown that Campylobacter is able to
survive outside of a host for an extended period of time, and that it is more likely
that chicks are colonized when exposed to C. jejuni in the environment (Murphey,
Carroll, & Jordan, 2006; Newell, 2002; Sahin, Morishita, & Zhang, 2002).
The most common mode of transmission of Campylobacter to humans in
the developed world is through the consumption of undercooked poultry meat,
which typically becomes contaminated during the slaughtering process when C.
jejuni from the intestines comes into contact with the meat (Friedman et al., 2000;
Humphrey, O’Brien, & Madsen, 2007). Once ingested, Campylobacter must
invade the intestinal mucosa and adhere to intestinal epithelial cells. When the
submucosa and nearby tissues are reached, bacteria are able to reach essential
nutrients such as iron, and peristaltic forces no longer reach the bacteria, making
it drastically easier to stay attached to the host. How Campylobacter is able to
reach this area of the intestines is still a mystery, but it is known that flagellum,
serine protease HtrA, and lipooligosaccharide play a role in C. jejuni invasion
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(Backert et al., 2013). Once Campylobacter has managed to adhere to the
intestinal epithelium, it induces diarrhea in its host. This increases its spread
throughout the host intestines as well as to new hosts (Young, Davis, & Dirita,
2007; van Putten et al., 2009; Dasti et al., 2010).

Antibiotic Resistance in Campylobacter
Campylobacter antibiotic resistance is on the rise, with resistance to
fluoroquinolone antimicrobials such as ciprofloxacin being reported most
frequently in several countries (Engberg et al., 2001; Moore et al., 2006;
Alfredson & Korolik, 2007). In the United States and Canada, ciprofloxacin
resistance is estimated to be around 19-47% (Gaudreau & Gilbert, 2003; Gupta
et al., 2004; Nachamkin, Ung, & Li, 2002), while in Europe ciprofloxacin
resistance is widespread and may be as high as 99% in human and animal
isolates (Alfredson & Korolik, 2007; Papavasileiou et al., 2007; Gallay et al.,
2007; Hakanen et al., 2003; Krausse & Ullmann, 2003). A more recent study
confirms the accuracy of these estimates, stating that ciprofloxacin resistance in
human Campylobacter isolates is around 23% in Montreal, and does indeed
appear to be rising (Gaudreau et al., 2014). Investigations in Germany, Ireland,
and Italy have yielded similar results (Luber et al., 2003; Lucey et al., 2002;
Pezzotti et al., 2003). In Africa and Asia, fluoroquinolone-resistant
Campylobacter was not found before 1991, but is now highly prevalent, with
resistance rates over 80% in some parts of Thailand and Hong Kong (Isenbarger
et al., 2002; Putnam et al., 2003; Tjaniadi et al., 2003; Chu et al., 2004).
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Fluoroquinolone resistance in Australia and New Zealand is much lower than in
other countries, but is still present at low rates (around 3%). However, this is
typically associated with Campylobacter infection acquired during travel. This
lack of resistance is likely due to it being unlawful to distribute fluoroquinolones to
food animals in Australia (Unicomb et al., 2003).
In addition to fluoroquinolone resistance, some Campylobacter strains
have acquired resistance to macrolides, but this appears to depend greatly on
the strain as well as the animal from which it was isolated (Belanger & Shyrock,
2007). For instance, in North America erythromycin (the most commonly used
macrolide against Campylobacter) resistance is normally around 10%. However,
in C. coli found in turkeys and pigs in the same regions, erythromycin resistance
was around 40% on average, with some instances of up to 80% (Luangtongkum
et al., 2006; Thakur & Gebreyes, 2005). Similarly, throughout Europe macrolide
resistance is low in Campylobacter, except for C. coli isolated from chickens and
pigs, which has resistance rates up to 80% (Papavasileiou et al., 2007; McGill et
al., 2006; Bardon et al., 2008; Gibreel & Taylor, 2006). In Asia and Australia, as
in previously mentioned countries, macrolide resistance is mostly found in C. coli
isolated from pigs (Miflin, Templeton, & Blackall 2007; Hong et al., 2007; Senok
et al., 2007; Shin & Lee, 2007). In Africa, interestingly, erythromycin resistant
Campylobacter is more commonly isolated from humans than from any food
animal (Gibreel & Taylor, 2006; Samie et al., 2007; Kassa, Gebre-Selassie, &
Asrat, 2007).
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Although the major antibiotics used against Campylobacter are
erythromycin and ciprofloxacin, it is important to note that many strains of
Campylobacter have been found to be resistant to additional antibiotics that are
less often used for this type of infection. Resistance to tetracycline in broilers is
seen to change with age. One study reported that Campylobacter isolated from
broilers 3-4 weeks old was not resistant to tetracycline, while 66.7% of isolates
from 5-week-old chicks were resistant and 100% of isolates from chicks 6-7
weeks old were resistant. Resistance prevalence then decreases and levels off
around 10-15% in mature chickens (Luangtongkum et al., 2008). This may be
due to the initial time Campylobacter is attempting to colonize, followed by a
spike, where the maximum amount of Campylobacter is present (and thus the
maximum amount of gene transfer can occur), and then a leveling off.
Tetracycline resistance is widespread and reported at relatively high numbers46% in Finland (Hakanen et al., 2003), 37.8% in Germany (Luber et al., 2003),
and 43-68% in Canada (Gaudreau & Gilbert, 2003). Similar to erythromycin
resistance, streptomycin resistance appears to be most prevalent in C. coli
strains isolated from pigs, and is not as prevalent as other antimicrobial
resistances (Pezzotti et al., 2003; McGill et al., 2006). Ampicillin resistances in
Campylobacter isolates have also been reported in several countries, but
prevalence appears to vary greatly from country to country-17% in Finland
(Hakanen et al., 2003), approximately 50% in France (Gallay et al., 2007), and
31% in the United States (Luangtongkum et al., 2008). C. jejuni shows a higher
10

incidence of resistance than other Campylobacter strains (McGill et al., 2006).
Like most of the discussed antibiotic resistances, Campylobacter ampicillin
resistance is rising, particularly in human isolates (Luber et al., 2003).
Mechanisms of Antimicrobial Resistance
In Campylobacter, antimicrobial resistance can be gained either through
mutations or through horizontal gene transfer. Fluoroquinolone resistance in
Campylobacter is acquired via specific point mutations in DNA gyrase A, in what
is known as the “quinolone resistance-determining region” (Payot et al., 2006).
Other bacterial species such as Salmonella and Escherichia coli must have
multiple point mutations in DNA gyrase A to gain fluoroquinolone resistance, but
Campylobacter loses susceptibility to this antibiotic after just a single point
mutation (Luo et al., 2003). Macrolide resistance is more difficult for
Campylobacter to attain as it requires modification of a ribosomal target.
Resistance can occur via a point mutation in 23rRNA or in the L4 and L22
ribosomal proteins. Resistance can alternatively occur through enzyme-mediated
methylation of these sites (Gibreel & Taylor, 2006; Payot et al., 2006). However,
gaining macrolide resistance through ribosomal point mutations is far more
common, and only C. rectus is known to gain resistance via methylation (Roe,
Weinberg, & Roberts, 1995; Luangtongkum et al., 2009; Concoran et al., 2006).
Not all Campylobacter antibiotic resistance occurs via mutations. For
example, tetracycline resistance is conferred through the gene tet(O), which
encodes a ribosomal protection protein (Taylor et al., 1985). This is the only gene
11

in Campylobacter that is known to provide tetracycline resistance. The tet(O)
gene is common among various Campylobacter species and is present in
isolates from many different animals (Moore et al., 2006). This gene is thought to
have initially been acquired via horizontal gene transfer from either
Streptomyces, Streptococcus, or Enterococcus (Batchelor et al., 2004; Taylor,
Garner, & Allan, 1983). Campylobacter is highly resistant to beta-lactam
antibiotics due to its ability to produce beta-lactamase (Zhang & Plummer, 2008),
and also has intrinsic resistance to a variety of antibiotics such as bacitracin,
trimethoprim, and vancomycin (Taylor & Courvalin, 1988; Corry et al., 1995).
Additional Complications of Antibiotic Resistance
Antibiotic resistance in Campylobacter is becoming increasingly common,
making infections more difficult to treat. This resistance is probably due to
overuse of antibiotic treatments during Campylobacter infection, with no standard
dosage or length of treatment (Hessulf et al., 2016). Antibiotic resistance can
spread easily, even between different Campylobacter strains, via horizontal gene
transfer either in bacterial cultures (Jeon et al., 2008; Wilson et al., 2003) or in
chicken intestines (Avrain, Vernozy-Rozand, & Kempf, 2004; Boer et al., 2002).
Campylobacter effectively carries out conjugation at not only an intraspecies
level (Pratt & Korolik, 2005; Avrain, Vernozy-Rozand, & Kempf, 2004), but at an
interspecies and occasionally even an intergenous level (Gibreel, Skold, &
Taylor, 2004; Nirdnoy, Mason & Guerry, 2005). Many of the plasmids that
Campylobacter typically transfers via conjugation carry genes that confer
12

resistance to tetracyclines and aminoglycosides (Pratt & Korolik, 2005; Gibreel,
Skold, & Taylor, 2004). Antibiotic resistance in bacteria is often associated with a
fitness cost such as a reduced growth rate in antibiotic-free environments
(Luangtongkum et al., 2009). This does appear to be the case with lower levels
of erythromycin resistance in Campylobacter (Caldwell, Wang, & Lin, 2008).
However, it has been demonstrated that fluoroquinolone resistance in
Campylobacter is not only stable in the absence of antibiotics, but that
fluoroquinolone-resistant mutants actually have enhanced fitness as they are
able to effectively outcompete other strains in a chicken host (Luo et al., 2005).
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CHAPTER TWO
LITERATURE REVIEW

S100 Proteins
The CDC and WHO have classified Campylobacter as a serious threat to
public health due to the high number of reported infections each year, the
seriousness of both the infection and post-infectious complications, and
Campylobacter’s resistance to the clinically-important antibiotics ciprofloxacin
and azithromycin (Johnson, Shank, & Johnson, 2017). Because of this, it is
important to understand how Campylobacter affects its host and it is necessary
to consider non-antibiotic methods of treatment for this pathogen. One promising
solution is S100 proteins, which are commonly used as markers of
gastrointestinal inflammation (Leach et al., 2007). Some S100 proteins, such as
S100A12 (calgranulin C) and S100A8/S100A9 (calprotectin), are known to have
antimicrobial properties (Kehl-Fie & Skaar, 2010).
S100 proteins are regulators of several important cell processes in
vertebrates including energy metabolism, growth, motility, cell cycle regulation,
apoptosis, transcription, proliferation, differentiation, and inflammation. These
proteins are absent in invertebrates. There are currently around 20 different
known S100 proteins, all with the ability to bind calcium (Heizmann, Fritz, &
Schäfer, 2002; Donato et al., 2013). S100 proteins are named for their solubility
in 100% ammonium sulfate saturated solution at a neutral pH. They are small
14

(10-12 kilodaltons), acidic proteins that are classified by their two distinct EFhand calcium-binding regions (Sedaghat & Notopoulos, 2008). Binding calcium
allows them to regulate numerous intracellular and extracellular processes and
signaling pathways. In this way, they are physiologically necessary to keep
excess calcium out of certain pathways and to prevent the precipitation of
calcium (Donato et al., 2013). S100 proteins are typically activated by a specific
molecule such as a growth factor, cytokines, or toll-like receptor ligands. They
can be secreted from the cell, where they act as damage-associated molecular
pattern factors (DAMPs) or alarmins. Secreted S100 proteins help to regulate
innate and adaptive immune responses as well as cancer cell locomotion and
tissue repair under certain circumstances (Donato, 2007; Ehrchen et al., 2009;
Hsu et al., 2009; Sorci et al., 2011).
Each S100 protein has its own set of intracellular functions that are
upregulated and downregulated individually. These functions are often necessary
for proper cell function, but are extremely unrelated (Table 1). For example,
S100A1 is mainly expressed in skeletal muscle fibers, cardiomyocytes, and
neurons (Donato, 2001) and is important for the contractile function of these
muscles (Rohde et al., 2010), while S100A2 binds p53 proteins (proteins
responsible for regulating cell growth and proliferation), and thus is recognized as
a tumor-suppressing protein (van Dieck et al., 2009). S100 proteins have gained
increasing amounts of attention due to many of them, like S100A2, being
involved in cancer regulation. However, it is important to note that other S100
15

Table 1. Summary of S100 proteins. Each protein has an individual intracellular and extracellular
function that may or may not be related to one another and to the functions of other S100 proteins
(Donato et al., 2013).

Protein

Intracellular Function

Extracellular Function

S100A1

Muscle contraction, energy

Enhances Ca2+ influx

S100A2

Tumor suppression

Chemotactic for eosinophils

S100A3

Epitehlial cell differentiation

No known extracellular roles

S100A4

Cell survival, motility, and invasion

Cell migration, tumor growth

S100A5

No known intracellular roles

No known extracellular roles

S100A6

Cell proliferation

Regulates secretion

S100A7

Tumorigenesis

Innate immunity

S100A8

Immune response

Regulates inflammation

S100A9

Inhibits monocyte differentiation

Reduces inflammation

Calprotectin

Myeloid cell differentiation

Neutrophil chemotaxis

S100A10

Membrane protein trafficking

Macrophage recruitment

S100A11

Recombinational DNA damage

Chondrocyte differentiation

Calgranulin C

Vascular remodeling

Pro-inflammatory reactions

S100A13

Release of fibroblast growth factor

Secretion of FGF-1

S100A14

Cancer suppressor

Proliferation and apoptosis

S100A15

No known intracellular roles

Chemotactic for monocytes

S100A16

Adipogenesis

No known extracellular roles

S100B

Stimulate proliferation, inhibit

Protects neuronal cells

S100G

Cytosolic Ca2+ buffer

No known extracellular roles

S100P

Transendothelial migration of tumor

Tumor growth and drug

S100Z

No known intracellular roles

No known extracellular roles
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proteins carry out equally important functions, such as S100A11, which can
repair damage to recombinant DNA and can stimulate cell growth (Murzik et al.,
2008; Sakaguchi et al., 2008).
S100 proteins can be secreted from the cell and are found in many human
body fluids, such as semen, urine, saliva, and feces. Secreted S100 proteins are
usually associated with active disease states, and some of these proteins can
even be used as biomarkers for specific diseases (Mocellin, Zavagno, & Nitti,
2008; Foell, Wittkowski, & Roth, 2007; Gogas et al., 2009; Gazzolo & Michetti,
2010). S100 proteins have individual extracellular functions that may or may not
relate to their intracellular functions, and for some of these proteins, extracellular
function is determined by binding (Fritz et al., 2010). For example, S100A1 has
relatively similar functions both inside and outside of the cell, as it is important
intracellularly for muscle fibers and contraction, and extracellularly for calcium
influx to cardiomyocytes (Rohde et al., 2010; Reppel et al., 2005). S100 proteins
such as S100A2 has differing functions, as it is important for p53 binding
intracellularly, but plays a role in chemotaxis extracellularly (van Dieck et al.,
2009; Komada et al., 1996). Also, varying amounts of S100 proteins are required
to activate their target receptors, depending on the function to be performed
(Donato, 2007). Since they can be excreted under certain circumstances, some
S100 proteins may be used as disease markers, particularly for inflammation.
Such markers could be useful to indicate levels of neutrophils present and
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amount of phagocyte activation, which could indicate presence of inflammation
and possibly disease progression (Foell et al., 2004).

Calprotectin
Calprotectin is also known as the S100A8/S100A9 heterocomplex.
Intracellularly, S100A8 plays a role in the immune response that is not fully
understood (Donato et al., 2013). Studies have shown that S100A8 is necessary
for cell and/or immune function, as deleting this gene in mice is lethal as early as
the embryonic stage. Mice embryos lacking the S100A8 protein were infiltrated
with maternal cells prior to resorption (Passey et al., 1999). In some cells,
S100A8 can be found in the nucleus, and this protein accounts for approximately
20% of all neutrophil cytoplasm (Grimbaldeston et al., 2003). Macrophages take
up S100A8 when exposed to oxidative stress, and this process is increased
when the anti-inflammatory cytokine interleukin (IL)-10 is present (Donato et al.,
2013). Extracellularly, S100A8 helps to regulate inflammation, which it does by
repelling neutrophils via oxidation sensitivity (Sroussi et al., 2006), and may play
a role in maternal-fetal tolerance (Passey et al., 1999). Again, IL-10 upregulates
S100A8 activity, as does corticosteroid (Hsu et al., 2005; Endoh et al., 2009). In
contrast, S100A9 prevents reduction in telomerase activity that is caused by
S100A8 intracellularly (Rosenberger et al, 2007). This protein is also able to
inhibit dendritic cell and macrophage differentiation, and may contribute to tumor
growth by producing intracellular reactive oxygen species (ROS) (Cheng et al.,
2008). When S100A9 is depleted, neutrophils are unable to properly respond to
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certain chemoattractants, which can result in transendothelial cell migration (Vogl
et al., 2007; McNeill et al., 200). Like S100A8, S100A9 repels neutrophils once it
has been secreted. In this way, it is able to reduce inflammatory responses as
well as reducing neutrophil migration (Sroussi, Berline, & Palefsky, 2007). Some
evidence suggests that S100A9 may even be able to mediate the immune
response to a certain degree controlling the amount of B7 co-stimulatory
molecules are expressed on antigen presenting cells (Shimizu et al., 2011).
Certain functions performed by S100A8 and S100A9 are still performed in
the S100A8/S100A9 heterocomplex (calprotectin), while others are not. For
instance, intracellularly, calprotectin may play a role in myeloid cell differentiation
through kinase activity, which is similar to the function of S100A9 (Lagasse &
Weissman, 1992; Murano, Collart, & Huberman, 1989; Averill et al., 2011). The
S100A8/S100A9 heterocomplex also performs functions independent from either
S100A8 or S100A9 alone, such as intracellular transportation of unsaturated fatty
acids and arachidonic acid (Siegenthaler et al., 1997). Extracellularly, this
complex has been shown to be chemotactic for neutrophils (Ryckman et al.,
2003) and influential to the migration of several types of cells, such as myeloidderived suppressor cells and some tumor cells (Sinha et al., 2008; Hermani et
al., 2006). This indicates that unlike S100A9, the heterocomplex promotes a proinflammatory response. One study shows that calprotectin may also effect cell
growth and induce certain types of apoptosis (Seeliger, 2003).
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When S100A8 and S100A9 heterodimerize into calprotectin, both proteins
are stabilized. This stabilization results in elongation of the S100A9 C-terminal Dhelix, which causes tetramers to form. Formation of these tetramers causes two
high affinity zinc-binding sites to be exposed at the interface of the
S100A8/S100A9 subunits (Korndorfer, Brueckner, & Skerra, 2007). This
conformational change allows for metal sequestration, which is responsible for
calprotectin’s antimicrobial properties (Kehl-Fie et al., 2011). Specifically,
calprotectin has been shown to inhibit fungal species as well as Staphylococcus
aureus by chelating zinc and manganese (Hsu et al, 2009; Corbin et al., 2008). It
is also able to protect the skin from microbial invaders when produced by
keratinocytes (Hsu et al., 2009).

Calgranulin C
S100A12, commonly referred to as calgranulin C, is an S100 protein with
antimicrobial properties similar to calprotectin, but without a heterodimer form
(Donato et al., 2013). S100A12 can typically be found in neutrophils,
macrophages, and smooth muscle cells (Goyette & Geczy, 2010). Intracellularly,
S100A12 functions to mediate between cytoskeletal elements and membranes
(Vogl et al., 1999). Additionally, this protein binds calcium and appears to have
calcium-dependent chaperone/anti-chaperone properties, which aid in the
prevention of aldolase and GAPDH aggregation (Htakeyama et al., 2004).
S100A12 expression in skin cells appears to halt growth (Hitomi et al., 1998).
This is interesting, as S100A12 is also suspected to be involved in vascular
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remodeling, and there is evidence that many vascular smooth muscle cell
dysfunctions are associated with the overexpression of S100A12 (Hofmann
Bowman et al., 2010). Additionally, S100A12 overexpression in the airways has
the positive effect of reducing inflammation from allergies (Hofmann Bowman et
al., 2011).
The extracellular functions of S100A12 are arguably more difficult to study
than calprotectin, as rodents, the standard model for studying the functions of
S100 proteins in vivo, do not have this protein in their genomes (Fuellen et al.,
2004; Ravasi et al., 2004). It is known, however, that extracellular S100A12 is
chemotactic for monocytes and mast cells at low concentrations (Yan et al.,
2008), and that high levels of S100A12 can activate mast cells and IgE,
stimulating pro-inflammatory cytokine production (Yang et al., 2007). S100A12
can be activated by TNFD, IL-6, endotoxin, and LPS (Yang et al., 2001). In
addition to promoting a pro-inflammatory immune reaction, this protein is
important for fighting off parasites, as it is able to bind paramyosin which inhibits
parasite growth and motility (Moroz et al., 2009). Like calprotectin, many of the
functions of S100A12 are due to its ability to chelate zinc (Donato et al., 2013),
but instead of also binding manganese, S100A12 is able to bind copper
(Zackular, Chazin, & Skaar, 2015).
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The Role of Zinc in Campylobacter
Zinc is an important nutrient for animals, as too little leads to defects in
immune function and too much can be toxic (Prasad et al., 2007, Costello et al.,
1997). Since the S100 proteins calprotectin and calgranulin C are known to bind
zinc, and many microbes require zinc for growth, this zinc sequestration may be
what is responsible for their antimicrobial properties (Donato et al., 2013). This is
especially important in inhibiting Campylobacter, as this bacterium has its own
zinc-binding protein (ZnuA) and has been shown to require zinc for colonization
of the chicken gastrointestinal tract (Davis, Kakuda, & DiRita, 2009). In one
study, the ability of a C. jejuni 'znuA mutant strain to colonize chicks was
observed and it was shown that colonization ability, but not replication, was
greatly reduced in this mutant. Zinc-binding proteins isolated from the chicken
ceca were found to be responsible for inhibiting the growth of these mutants
(Gielda & DiRita, 2012).
Aside from its importance for colonization and virulence, little is known
about what specific functions zinc has in Campylobacter. In other
microorganisms, zinc is known to act as a catalyst for multiple proteins by
assisting in intramolecular interactions and protein folding (Si et al., 2017). Zinc
has also been shown to stabilize protein structures and is thus likely involved in
multiple cell functions (Berg & Shi, 1996). Not surprisingly, these roles make zinc
important for microbial growth and morphology, with additional evidence
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suggesting that zinc may also play a role in the regulation of certain
transcriptional factors in these species (Moulin et al., 2016).

Ferrets as a Model for Gastrointestinal Illness
Ferrets (Mustela putorius furo) are an ideal animal model to use for
Campylobacter infection because they are one of the few animals that produce
clinical signs similar to symptoms in humans when infected, such as self-limiting
diarrhea. Younger animals (approximately 6-7 weeks old) are ideal models as
they produce more severe diarrhea upon infection (Bell & Manning, 1990).
However, both young and adult ferrets will produce signs of disease (Burr et al.,
2005). Commonly used rodents such as rabbits and germ-free mice can be used,
but must be genetically manipulated prior to infection (Yrios & Balish, 1986;
Caldwell et al., 1983). Additionally, ferrets are susceptible to post-infections
complications from Campylobacter, such as inflammatory bowel disease (IBD)
(Burgess, 2007). However, great care must be taken when studying these
animals, as slight dietary changes may also produce IBD symptoms (Watson et
al., 2016). Unfortunately, aside from descriptions of gastrointestinal symptoms,
the literature available on Campylobacter-infected ferrets is lacking, and much of
it is outdated, including information regarding the immune response to disease in
these animals.

23

CHAPTER THREE
MATERIALS AND METHODS

Animals
Twelve weaning-aged ferrets (5.5-6 weeks of age), six males and six
females, were obtained from Marshall BioResources (North Rose, N.Y.). Ferrets
were individually housed at the Walters Life Sciences (WLS) Animal Facility at
the University of Tennessee Knoxville. They were acclimated in the WLS animal
facility for seven days to allow the animals to recover following transportation.
Ferrets were fed Envigo Teklad global ferret diet and given water ad libitum
throughout this study, except for restriction 2-3 hours prior to inoculation with
Campylobacter jejuni.

Bacterial Cultures and Inoculation
The principal C. jejuni strain used in this study was 81-176. This strain
was grown on Campylobacter-specific media and Gram strained to ensure purity
of the culture. The pure culture was then streaked again on Campylobacterspecific media and incubated at 37qC under microaerophilic conditions for 24
hours. Six suspensions of C. jejuni 81-176 were made in 5mL phosphatebuffered saline (PBS) and diluted to OD600 2. Ferrets were anesthetized with
isoflurane and inoculum was administered via orogastric tubing and 12mL
syringe. Six ferrets were infected with 5mL C. jejuni 81-176 OD600 2 in PBS
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combined with 5mL 5% sodium bicarbonate buffer. Six ferrets were mock
infected with 5mL PBS combined with 5mL 5% sodium bicarbonate buffer.
Morphine was administered to each ferret approximately one hour following
inoculation.

Sample Collection and Campylobacter Enumeration
Ferrets were weighed and measured once per week post-infection. Fecal
and serum samples were collected on days 1, 3, 6, 7, 9, 12, and 14 postinfection, followed by samples collection once per week. Three fecal samples
were collected from each cage per time point in the morning. Approximately
200mg of feces from one sample from each animal was immediately weighed out
and diluted 1:100 in PBS. The remaining samples were immediately frozen at 80qC. Diluted samples were further serially diluted in PBS to 10-8 and 100PL of
each dilution was plated on Campylobacter-specific media. These plates were
then incubated at 37qC in microaerophilic conditions for 48 hours before
Campylobacter loads were determined.
Ferrets were individually anesthetized with isoflurane prior to blood
collection. Blood was drawn from the vena cava and was limited to 0.2% of the
animal’s body weight for time points during days 1-14 post-infection, followed by
1.5% of the animal’s body weight for blood draws once per week. After each
collection, blood was allowed to clot in an upright position for at least 20 minutes.
Samples were then centrifuged at 3500 rpm for 15 minutes. Serum was then
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pipetted into clean 1.5mL Eppendorf tubes and frozen at -80qC. The remainder of
the clotted sample was disposed of.

Serum Assay
Serum samples collected days 1 through 14 were analyzed at Vanderbilt
University Medical Center (VUMC) using a Luminex mouse cytokine 1 panel. For
this assay, a 96-well plate was washed prior to adding standards and samples.
The appropriate matrix was then added to the wells, followed by antibody
immobilized beads. The plate was then incubated overnight (16-18 hours) on a
shaker at 4qC. After this incubation, plate contents were removed and the plate
was washed three times with buffer. Detection antibody was then added to each
well and the plate was shaken for one hour at room temperature. Following
incubation, Streptavidin-Phycoerythrin was added to each well and the plate was
incubated for 30 minutes at room temperature with shaking. The contents of the
plate were removed and the plate was washed three times with buffer. After
washing, drive fluid was added to each well and the plate was shaken at room
temperature for five minutes. Finally, the plate was read on a MAGPIX using
EXPONENT software and results were analyzed using Milliplex Analyst software.
Using this method, levels of IL-1E, IL-10, IL-12p40, and TNFD were compared in
uninfected and infected ferret samples.

26

Fecal Assays
Several assays were performed on fecal samples from the first 7 time
points (days 1 through 14 p.i.). An occult blood test was performed using a
Beckman Coulter Hemoccult II test kit. This procedure involved smearing a thin
layer of feces over the specified box, incubating 3-5 minutes, applying two drops
of Hemoccult Developer solution, and reading the result within 60 seconds.
Results were subjectively scored using “0” as a negative, “0.5” as a weak
positive, and “1” as a strong or regular positive, which is shown as
presence/absence of blue coloring. Positive and negative controls were included
on the test strips for each sample box.
Levels of S100A12, calprotectin, and D1-protease inhibitor were also
analyzed in ferret fecal samples. To analyze S100A12, protease inhibitor tablets
were dissolved in PBS (one tablet per 15mL PBS). Approximately 0.5g of each
fecal sample was weighed out in a falcon tube and 5mL of the protease inhibitor
mixture was added to each sample. Samples were then vortexed vigorously and
50PL of each sample was used in a LifeSpan BioSciences, Inc. human S100A12
ELISA kit. This same procedure was performed to measure S100A12 levels in
Campylobacter-infected and uninfected human fecal samples as well. A similar
procedure was used to measure levels of calprotectin in infected and uninfected
ferret and human fecal samples, with the modification of weighing out 0.1g feces
and adding 1mL protease inhibitor mixture. Additionally, we performed a 1:10
dilution with our samples (in sample diluent supplied in the LifeSpan
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BioSciences, Inc. ELISA kit) to obtain results within the range of the kit (the upper
detection limit was 2000pg/mL). Absorbance of the samples was determined
using a plate reader immediately following the final step of the ELISA. ELISA
plates were read at wavelength 450nm, with 620nm as the reference wavelength.
To measure D1-protease inhibitor levels in ferret fecal samples, a canine (Texas
A&M) immunoassay and a human (Biovendor) ELISA kit were used.

C. jejuni Growth in the Presence of S100 Proteins in vitro
Dose response assays were performed on C. jejuni wild-type strain
DRH212 using S100A12 or calprotectin as a growth inhibitor. Concentrations of
S100A12 and calprotectin started at 1000Pg/mL and were serially diluted (1:1 in
Helicobacter pylori media) to 15.625Pg/mL to determine the minimal
concentration necessary to inhibit C. jejuni growth. These assays were carried
out in triplicate using Helicobacter plylori media (Brucella broth with fetal bovine
serum and calprotectin buffer) as the growth medium. For each
S100A12/calprotectin concentration, 100PL of diluted protein was added to
100PL of OD600 0.5 C. jejuni in a 96-well plate. These plates were read at 600nm
following 24-hour and 48-hour incubation in a microaerophilic environment at
37qC.

28

Restoration of C. jejuni Growth Following Treatment with S100
Proteins
Once minimal inhibitory concentrations of S100A12 and calprotectin
(500Pg/mL) were determined, assays were carried out with the wild-type
DRH212 C. jejuni strain and the minimal inhibitory concentration of S100A12 or
calprotectin. Elements known to bind to or be sequestered by S100A12 or
calprotectin were added to the wells at a concentration of 100PM. For S100A12,
100PL of 100PM CuCl2, CaCl2, and ZnCl2 were added to a 100PL mixture of
OD600 0.5 DRH212 with 500PL S100A12. Plates were incubated in a
microaerophilic environment at 37qC and read at 600nm following 24-hour and
48-hour incubation to determine if any of these elements could restore C. jejuni
growth in vitro following S100A12 treatment. The same procedure was used to
examine elements that can restore C. jejuni growth in vitro following treatment
with calprotectin. The only modification was MnCl2 was used in place of CuCl2,
as per binding specificity of this protein. Knock-out calprotectin was also used in
this assay to ensure that the solution itself was not responsible for the inhibition
of C. jejuni growth.

RNAseq Analysis of S100A12-Treated C. jejuni
C. jejuni (strain DRH212) was incubated overnight at 37qC on two
separate Mueller-Hinton agar plate containing 10Pg/mL trimethoprim. Two more
DRH212 cultures were incubated in identical conditions, but these had been
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previously treated with 500Pg/mL purified S100A12. Following this incubation, all
four samples were suspended in 40mL Mueller-Hinton broth and each was
diluted to OD600 1. These samples were then incubated at 37qC for approximately
six hours. Samples were then centrifuged at 4000 rpm for 10 minutes. The
supernatant was discarded and the pellet was resuspended in 1mL Trizol.
Samples were frozen at -80qC until RNA extraction.
To RNA extract, the two wild-type DRH212 and the two S100A12-treated
DRH212 samples were first thawed on ice until they were completely melted.
They were then incubated at room temperature for five minutes. 100PL of
chloroform was added to each sample and samples were vortexed. Samples
were again incubated at room temperature for five minutes, followed by
centrifugation at 15,000 rpm for five minutes at 4qC. 700PL of 100% isopropanol
was added to fresh Eppendorf tubes. The aqueous phase was then removed
from each centrifuged sample and added to the respective aliquots of
isopropanol. These were vortexed briefly and centrifuged at 15,000 rpm for 10
minutes at 4qC. Supernatant was discarded, while the pellets were resuspended
in 150PL of 70% isopropanol. Samples were centrifuged at 15,000 rpm for five
minutes at 4qC. All supernatant was then removed and discarded and pellet was
air dried for approximately 15 minutes. Finally, pellets were resuspended in 50PL
deionized RNase-free water and frozen at -20qC.
Samples were DNase-treated to ensure that only RNA was present. To
DNase-treat, 20PL DNase I 10x reaction buffer was added to 30Pg of each
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thawed RNA-extracted DRH212 sample. 8PL DNase was added to each mixture
and they were each brought to a volume of 200PL by adding RNase-free
deionized water. Samples were incubated in a 37qC heat block for 30 minutes,
8PL additional DNase was added, and the incubation was repeated. Samples
were cleaned using a Zymo RNA clean and concentrate kit. Samples were then
PCR’d to check for the presence of DNA (indicated by bands). DNA was still
present, so 1PL DNase and 1PL DNase I 10x reaction buffer was added to each
sample. Samples were incubated at 37qC for 30 minutes, 1PL additional DNase
was added to each, and the incubation was repeated. Samples were then RNA
cleaned and PCR’d once again to check for presence of DNA. The DNasetreatment, RNA clean, and PCR were repeated once more before samples could
be confirmed to be purely RNA.
The four DNA-free samples were treated with an Illumina Ribo-Zero
Magnetic Kit to remove rRNA. DNA libraries were then made from each RNA
sample using a MiSeq Reagent Kit v3 and following the provided protocol.
Samples were checked for good quality using a bioanalyzer. DNA libraries were
labelled with individual indexes, run through a MiSeq, and results were analyzed
for changes in gene regulation between wild-type DRH212 and S100A12-treated
DRH212.
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CHAPTER FOUR
RESULTS AND DISCUSSION
Sample Collection and Campylobacter Enumeration
Campylobacter-infected ferrets did not significantly differ from uninfected
ferrets in length or weight (Figures 1A and 1B). As expected, males were
significantly larger and heavier than females, and lengths and weights of these
animals increased steadily over the period of the experiment. Following oral
challenge with C. jejuni, Campylobacter loads in infected ferrets peaked at day 3
post infection (p.i.). C. jejuni could no longer be detected by day 12 p.i. and there
were no clinical signs of infection by this time (Figure 2). This peak and duration
of infection is consistent with previous studies using ferrets as a disease model
for Campylobacter infection (Bell & Manning, 1990; Nemelka et al., 2009). Using
our screening methods, the limit-of-detection for Campylobacter was at 2.0 X 103
CFU/g of feces. C. jejuni could not be detected in uninfected ferret feces at any
time point and thus are not shown. Ferrets did not have frank blood present in
their stools at any time point. Some infected ferrets displayed mildly watery stool
early in infection, but no severe diarrhea was observed throughout the
experiment.
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Figure 1. Effect of C. jejuni infection on growth and development of ferrets. Comparison of ferret
weight (A) and length (B). Data was analyzed with unpaired student’s t-tests using the HolmSidak method with D=0.05 (n=3).
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Figure 2. C. jejuni loads in feces of infected ferrets. Immediately after collection, fecal samples
were serially diluted (1:10) in PBS. Dilutions were then plated on Campylobacter-specific media
and incubated 48 hours at 37qC. The horizontal bars represent the average C. jejuni loads found
in feces of infected ferrets.

34

Serum Assay
We initially analyzed serum samples from days 6 and 7 (the height of
infection) for the levels of 7 cytokines (interferon-J, IL-1E, IL-6, IL-10, IL-12p40,
IL-12p70, and TNFD) using a Luminex mouse cytokine panel. We chose our
samples based off a previous study looking at cytokine production during C.
jejuni infection in human dendritic cells (Hu et al., 2006). We determined that IL1E, IL-10, IL-12p40, and TNFD were the most elevated from baseline, so we
analyzed the levels of these four cytokines in serum samples from days 1-14.
When we compared all seven sets of sera from the initial time points, we saw a
significant increase in levels of IL-10 (an anti-inflammatory cytokine) at days 1, 3,
9, and 12 in infected ferrets. We saw a significant increase in TNFD (a proinflammatory cytokine) at days 1, 3, 6, and 7 in infected ferrets (Figure 3). There
was no significant difference in levels of IL-1E or IL-12p40 in infected versus
uninfected ferrets at any time point.
Infected ferrets showed a significant increase in the levels of both IL-10
and TNFD present in serum. A large increase in TNFD production during early
Campylobacter infection was also seen in a previous study (Hu et al., 2006). In
this same study, IL-10 was also shown to increase significantly, but only at the
latest time point (48 hour). Initially, we observed that significantly higher levels of
TNFD were produced in C. jejuni infected ferrets (days 1, 3, 6, and 7). This
signifies an increase in intestinal inflammation early in infection, since TNFD is a
pro-inflammatory cytokine secreted by macrophages to induce an inflammatory
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state. In addition to its upregulation during enteric pathogen infection (such as
Campylobacter and Salmonella), TNFD is seen to be elevated in chronic
inflammatory disorders such as inflammatory bowel disease and rheumatoid
arthritis (van der Veek et al., 2005). IL-10, an anti-inflammatory cytokine, has a
relatively unknown mechanism of action, but has been seen to successfully
inhibit inflammatory responses. Additionally, IL-10 is thought to play a role in the
prevention of inflammatory bowel disease, as both humans and mice with
deficient IL-10 display severe intestinal inflammation (Ip et al., 2017). IL-10 levels
were significantly elevated in infected ferrets towards the very beginning and at
the end of infection (days 1, 3, 9, and 12). This indicates that IL-10 is initially
elevated to keep the TNFD levels regulated and inflammation in control. IL-10 is
also elevated late in infection in order to reduce the immune response back to
baseline once most of the infection has cleared.
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Figure 3. Cytokine levels in ferret serum. (A) IL-1β; (B) IL-10; (C) IL-12p40; (D) TNFα. Cytokine
levels were measured at Vanderbilt University Medical Center using the Luminex platform and
mouse cytokine panel 1. *p<0.05, Mann-Whitney U test, n=6.
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Fecal Assays
Occult blood is blood in stool that is not visible to the naked eye. Occult
blood tests were performed on all ferret fecal samples from days 1-14 using a
Beckman Coulter Hemoccult II test kit. Tests were scored based on the presence
of blue coloring, with “0” meaning negative (no blue present), “0.5” meaning a
weak positive (some blue, usually more towards the edge of the sample), and “1”
being a normal or strong positive (deep blue coloring, typically present
throughout the entire sample spot). Although there was no significant difference
in occult blood scores at any time point for infected versus uninfected ferrets,
infected samples from days 1, 12, and 14 appeared to have a higher incidence of
occult blood (Figure 4). We suspect that uninfected ferrets may have had occult
blood in their fecal samples due to stressors and lack of dietary restriction prior to
testing, which have been seen to play a role in the motility and amount of
secretion of the ferret gastrointestinal tract (Johnson-Delaney, 2006).
Neither a canine immunoassay nor a human ELISA for D1-protease
inhibitor was able to find any detectable levels of this protein in any of the ferret
fecal samples at any time point (data not shown). Amount of D1-protease
inhibitor in human feces was not determined. Our inability to detect an elevated
amount of D1-protease inhibitor in any of the ferret samples using human or
canine antigens may be a binding specification error. However, we consider this
to indicate that D1-protease inhibitor levels during C. jejuni infection in humans
cannot be accurately modeled in ferrets.
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Figure 4. Occult blood found in ferret feces via Hemoccult II test. A score of 1 was positive, 0.5
was a weak positive, and 0 was a negative. There were six ferrets per group per time point. Data
was compared using a Mann-Whitney U test with D=0.05 (n=6).
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To evaluate levels of calprotectin in ferret and human fecal samples, a
LifeSpan BioSciences, Inc. ELISA kits for calprotectin was used. Using a MannWhitney U test (p<0.05), neither C. jejuni infected ferret fecal samples at any time
point nor C. jejuni infected human fecal samples were found to have significantly
higher levels of calprotectin when compared to the uninfected samples (Figures
5A and 5B). Almost all ferret fecal samples had undetectable levels of
calprotectin, while nearly all human fecal samples appeared to have normal
levels of calprotectin (<50Pg/g). This was likely due to a lack of binding specificity
between the ferret antigens in the fecal samples and the human antibodies in the
ELISA kit. The lack of elevation of calprotectin in infected human samples could
be due to the use of an ELISA kit with improper detection levels. However,
calprotectin is known to be an inaccurate biomarker when low levels of
inflammation are present, and may also be drastically effected by the use of
NSAIDS (Siddiqui, Majid, & Abid, 2017). Using our methods, we cannot
accurately model calprotectin levels of C. jejuni infected humans in ferrets.
S100A12 levels in ferret and human fecal samples were evaluated using a
LifeSpan BioSciences, Inc. ELISA kit for S100A12. At day 7 post-infection,
infected ferret fecal samples were shown to have a 2-fold increase of S100A12
present compared to uninfected ferret fecal samples (Figure 6A). This result was
found to be significant using an unpaired two-tailed Student’s t-test with Welch’s
correction (p<0.05). No infected ferret fecal samples from any other time points
had significantly elevated S100A12 levels compared to uninfected fecal samples.
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This makes sense with the Campylobacter loads we saw, as this time point
would be just after peak infection. Using these same methods, human fecal
samples were also found to have a statistically significant (p<0.05),
approximately 2-fold, increase in S100A12 levels when infected with
Campylobacter versus those uninfected (Figure 6B). Since S100A12 levels in
ferrets reflect the 2-fold increase in infected compared to uninfected samples that
is shown in humans, we can conclude that ferrets can be used to model the
effects of S100A12 during C. jejuni infection in humans. This is useful as
S100A12 is as accurate as calprotectin in identifying intestinal inflammation, but
with greater specificity, and therefore less false-positives (Sidler, Leach, & Day,
2008).
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Figure 5. Calprotectin concentrations in fecal samples. (A) Ferrets at day 7 post-infection (n=6).
(B) Human feces submitted to the University of Nebraska Clinical Microbiology Laboratory (UTK
IRB-17-03795-XM) (n=7). Data was compared using a Mann-Whitney U test with D=0.05.
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B

A

Figure 6. S100A12 concentrations in fecal samples. (A) Ferrets at day 7 post-infection (n=6). (B)
Human feces submitted to the University of Nebraska Clinical Microbiology Laboratory (UTK IRB17-03795-XM). Data was compared using an unpaired two-tailed Student’s t-test with Welch’s
correction with D=0.05.
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C. jejuni Growth in the Presence of S100 Proteins in vitro
Both calprotectin and calgranulin c (S100A12) were able to significantly
inhibit C. jejuni growth in vitro (Figure 7). A knock-out calprotectin mutant created
by Dr. Steve Damo at Fisk University was used to ensure that C. jejuni growth
was not inhibited by factors other than metal sequestration. At the highest
concentration (1000Pg/mL), the knock-out mutant was able to significantly reduce
growth, suggesting that the suspension media may have played a role in
inhibition. However, the knock-out mutant did not inhibit growth at any other
concentration, while both calprotectin and calgranulin c were able to inhibit
growth at 500Pg/mL. Additionally, calprotectin could significantly inhibit C. jejuni
growth at concentrations as low as 250Pg/mL.
Calprotectin and calgranulin c (S100A12) inhibited C. jejuni growth in vitro
at concentrations as low as 250Pg/mL and 500Pg/mL, respectively. The
resuspension media that these proteins were stored in (PBS) may have slightly
inhibited growth, as indicated by C. jejuni growth inhibition by a knock-out
calprotectin mutant at 1000Pg/mL. However, at concentrations lower than
1000Pg/mL, no inhibition was seen in C. jejuni that was treated with the knockout mutant. This confirms that we are indeed seeing growth inhibition caused by
the S100 protein treatments. Calprotectin and calgranulin c are known to have
antimicrobial properties, possibly due to their ability to sequester necessary
elements such as manganese, copper, and zinc (Kehl-Fie & Skaar, 2010). This
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Figure 7. S100 protein inhibition of C. jejuni growth in vitro. Dose response analysis using purified
S100A12 (calgranulin C), calprotectin, or a knock-out calprotectin mutant. C. jejuni cultures were
treated with one of the three compounds and growth was compared to that of untreated C. jejuni
cultures (*p<0.01, Mann-Whitney U test, n=3).
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implies that the C. jejuni growth inhibition we have seen is due to the necessity of
these elements in Campylobacter survival.

Restoration of C. jejuni Growth Following Treatment with S100
Proteins
C. jejuni isolates were treated with 500Pg/mL of either calprotectin or
calgranulin c. C. jejuni was then supplemented with 100PM calcium, zinc, and
either manganese (calprotectin-treated) or copper (calgranulin c-treated) to see if
these compounds could restore growth (Figures 8A and 8B). Calprotectin-treated
C. jejuni grew significantly less than C. jejuni treated with a control (PBS).
Calcium failed to restore growth in C. jejuni. Manganese was able to restore
growth enough to not be significantly different from the control, while C. jejuni
treated with zinc grew significantly better than the C. jejuni treated with the
control. Likewise, calgranulin c-treated C. jejuni grew significantly less than C.
jejuni treated with PBS. Neither copper nor calcium was able to significantly
restore growth. Cultures treated with zinc again grew significantly better than
those treated with the control. These results hint at the mechanism of action for
these S100 proteins and indicate that either calcium and copper are not
necessary for C. jejuni growth, or that S100 proteins are not as successful at
sequestering these elements as previously thought.
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RNAseq Analysis of S100A12-Treated C. jejuni
Using RNAseq, S100A12-treated and untreated C. jejuni (strain DRH212)
cultures were analyzed for differential gene expression. Surprisingly, we did not
see any upregulation in zinc transportation systems when comparing S100A12treated cultures to untreated cultures. We expected the S100A12 treatment to
cause an increase in these systems from our hypothesis that S100A12 blocks
zinc uptake, which was formulated from our in vitro analysis of S100A12-treated
C. jejuni cultures. We saw 15 different upregulated systems in S100A12-treated
cultures, with energy production and conversion most frequently upregulated
(Figure 9A). Four different systems were downregulated in the S100A12-treated
cultures, with translation and ribosomal structure and biogenesis accounting for
over half of all downregulated genes (Figure 9B). However, this system also
appears to be upregulated in treated cultures, which suggests multiple genes are
responsible for these functions in Campylobacter, and not all of these gene
pathways are inhibited by S100A12. Likewise, cell wall/membrane/envelope
biogenesis was seen to be both upregulated and downregulated. This
unexpected outcome may be due to the short treatment time of DRH212 with
S100A12 (six hours). A longer treatment time as well as a higher S100A12
dosage (we used the minimal inhibitory concentration of 500Pg/mL) may help us
to more accurately predict changes in gene regulation of C. jejuni that has been
treated with S100A12. Alternatively, zinc may not be necessary throughout
different Campylobacter growth phases. To test for this, the S100A12 treatment
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should be repeated and gene transcription should be monitored at different time
points across multiple different growth phases. RNA seq may not be a viable
method to determine this, but quantitative real-time PCR could be a favorable
alternative. Zinc transporter upregulation may be happening at a translational,
not transcriptional, level instead. If this is the case, it would be useful to observe
Western blots and reverse transcription PCR of S100A12-treated and untreated
C. jejuni cultures.
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Figure 9. Differences in gene regulation of S100A12-treated C. jejuni and untreated C. jejuni,
analyzed using RNA seq. Levels of gene transcription were compared to levels in untreated C.
jejuni cultures. (A) Upregulated genes (n=32). (B) Downregulated genes (n=7).
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CHAPTER FIVE
CONCLUSIONS AND RECOMMENDATIONS
Campylobacter is a leading cause of bacterial-derived gastroenteritis
worldwide, costing approximately $1.7 billion annually in the United States alone
(Johnson, Shank, & Johnson, 2017). In the developed world, campylobacteriosis
is most commonly acquired through the consumption of contaminated poultry
meat (Johnson et al., 2015). Little is known about how Campylobacter is able to
successfully invade and colonize its hosts, though it typically resides in cecal
mucosal crypts (Coward et al., 2008). Campylobacteriosis is a serious concern,
as it can lead to several severe post-infectious complications such as GuillainBarré syndrome, septicemia, reactive arthritis, and inflammatory bowel diseases
(Goldstein et al., 2016; Kaakoush et al., 2014). Additionally, antibiotic-resistant
Campylobacter prevalence has been steadily increasing around the world
(Engberg et al., 2001; Moore et al., 2006; Alfredson & Korolik, 2007), which is
likely due to the overuse of antibiotics (Hessulf et al., 2016).
A possible non-antibiotic Campylobacter treatment involves the use of
S100 proteins, particularly calprotectin (S100A8/S100A9) and calgranulin C
(S100A12). These proteins are used as biomarkers to detect the presence of
inflammation, as they are commonly secreted from neutrophils (Leach et al.,
2007). Additionally, these proteins are known to have antimicrobial properties
(Kehl-Fie & Skaar, 2010). This may be due to their ability to bind calcium and to
sequester metals such as zinc, manganese, and copper (Zackular, Chazin, &
Skaar, 2015).
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We decided to observe levels of S100 proteins both in vitro and in vivo to
determine their possible effects on Campylobacter jejuni. For our in vivo studies
we used ferrets as a model for human infection due to their being one of the only
animals to produce similar clinical signs to humans following infection with
Campylobacter (Bell & Manning, 1990). We did not observe any noticeable
differences in the sizes of infected versus uninfected ferrets. We observed peak
Campylobacter loads at three days post-infection. We saw a significant increase
in the levels of IL-10 at the beginning and end of infection, and in TNFD at the
initial time points following infection. This indicates a strong pro-inflammatory
immune response caused by TNFD, while IL-10, an anti-inflammatory cytokine,
was likely regulating the immune reaction. There was no significant increase in
occult blood between infected versus uninfected ferrets, but this could be due to
the sensitivity of the ferret digestive tract (Watson et al., 2016). Finally, we did not
observe a significant increase in calprotectin, but we did see significantly
elevated levels of calgranulin C in infected ferrets at peak infection. This
indicates that ferrets are a viable animal model for human campylobacteriosis
due to their reflection of calgranulin C levels in humans during infection.
Our in vitro observations of the effects of calprotectin and calgranulin C on
Campylobacter jejuni show that each of these proteins can effectively inhibit
growth. Calgranulin C inhibits growth at concentrations as low as 500Pg/mL,
while calprotectin can inhibit growth with as little as 250Pg/mL. Following this
experiment, we supplemented back metals known to be sequestered by these
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proteins to help determine a possible mechanism of action for Campylobacter
inhibition. Following treatment with 500Pg/mL of calgranulin C, we saw that
100PM of zinc was able to significantly restore C. jejuni growth, while 100PM of
calcium or copper could not. Similarly, when C. jejuni was treated with 500Pg/mL
calprotectin, 100PM of zinc was able to significantly restore growth. Additionally,
100PM of manganese was able to restore calprotectin-treated C. jejuni growth,
while 100PM of calcium was not. MiSeq was used to determine which genes
were being upregulated and downregulated in response to calgranulin C
treatment, but we did not get the results we expected, which would have shown
us upregulation of a zinc transporter or related gene. Instead, we observed that
the most commonly upregulated genes in calgranulin C-treated C. jejuni were
genes involved in energy production and conversion. The most commonly
downregulated genes were those involved in translation and ribosomal structure
and biogenesis. A longer calgranulin C treatment time (we only incubated for 6
hours) or a higher calgranulin C dosage (we used the minimal inhibitory
concentration of 500Pg/mL) may have produced clearer results. Alternatively, it
would be useful to look into Campylobacter zinc regulation across multiple
growth phases and at translational and post-translation zinc regulation.
In the future, it would be interesting to observe the effects of
Campylobacter on a malnourished host and to compare the effects to those of a
healthy host. This would be important to look at as source of infection, age
groups commonly infected, and post-infectious complications from
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Campylobacter differs greatly between first and third world countries.
Campylobacter infection in third world countries is common in children five years
old and younger and is typically acquired from contaminated drinking water
(Johnson, Shank, & Johnson, 2017). Persistence and stunting following
Campylobacter infection are more commonly seen in these areas of the world as
well (Amour et al., 2016). This implies that diet plays a key role in infection and
immune response to campylobacteriosis. We suspect that stunting may be
caused by a lack of zinc in the host, as some S100 proteins are seen to be
upregulated during infection and to bind zinc (Donato et al., 2013), and
Campylobacter is also known to scavenge zinc from its host environment (Davis,
Kakuda, & DiRita, 2009). Zinc deficiencies have been shown to lead to
imbalances in the immune system, particularly in children with diarrhea (Gielda &
DiRita, 2012).
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